ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
Regeneron bets big on Lynozyfic
The company is starting four new pivotal trials this year.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
